The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons
| Autor: | Felix Pavlotsky, Merav Lidar, Michal Brodavka, Aviv Barzilai, Itzchak Levy, Amit Druyan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Demographics COVID19 Dermatology Severity of Illness Index Asymptomatic Autoimmune Diseases 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans In patient Inflammation SARS-CoV-2 business.industry Mortality rate Significant difference corona virus 19 COVID-19 autoimmune Original Articles General Medicine Middle Aged inflammatory disease 030220 oncology & carcinogenesis Female Original Article medicine.symptom business |
| Zdroj: | Dermatologic Therapy |
| ISSN: | 1529-8019 1396-0296 |
| Popis: | Data regarding the risk for severe COVID19 in patients with autoimmune or inflammatory diseases are scarce. To estimate the risk of those patients to develop a more severe COVID19 infection All active patients and those with dermatologic and/or rheumatologic autoimmune/inflammatory diseases were identified in a single tertiary center. The charts of those tested positive for COVID19 between March 1st and May 31st, 2020 reviewed including demographics, co-morbidities and medications. COVID19 outcome of those with dermatologic and/or rheumatologic autoimmune/inflammatory diseases were compared to COVID19 infected matched controls without an autoimmune/inflammatory background. Overall, 974 of 381 268 active patients were tested positive for COVID19, including 35 out of 13 225 with dermatologic and/or rheumatologic autoimmune/inflammatory diseases. No statistically significant difference in severity of COVID19 infection or mortality rate was found. The rate of asymptomatic, mild, moderate, severe/critical and fatal COVID19 infection was 11.4%, 37.1%, 22.8%, 11.4% and 17.1% respectively for the patients with autoimmune diseases and 17.8%, 45.8%, 10.9%, 6.8% and 18.4% respectively for the controls . Patients with autoimmune/inflammatory diseases seem not to develop a more severe COVID19 infection than controls. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|